Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories SAN FRANCISCO, SAN DIEGO and CASTRES, France, March 01, 2024 - Kinnate Biopharma Inc. (Nasdaq: KNTE), a clinical-stage precision oncology company, and Pierre Fabre Mdicament, SAS (Pierre Fabre Laboratories), a global player in oncology, have announced their agreement to the sale of Kinnate's investigational pan-RAF inhibitor, exarafenib, and other pan-RAF program assets. This sale of global rights marks a significant development in Kinnate's strategic exploration of alternatives. Kinnate Biopharma Inc., known for its innovative approaches in precision oncology, has made headway in the field of cancer therapeutics. Through the sale of exarafenib and other pan-RAF program assets, Kinnate aims to leverage the expertise and global reach of Pierre Fabre Laboratories to further advance the development and commercialization of this promising precision medicine.
|